See the DrugPatentWatch profile for keytruda

Based on the information provided, there is no definitive answer regarding whether immunocompromised individuals are more prone to infusion reactions from Keytruda (pembrolizumab). However, it is important to note that infusion reactions are a known side effect of Keytruda, and healthcare providers should closely monitor patients for any symptoms during and after infusion [1].

Immunocompromised individuals may have a higher risk of developing adverse reactions to certain medications due to their weakened immune systems. However, the likelihood of infusion reactions specifically in this population in relation to Keytruda is not explicitly stated in the available information.

According to the drug's prescribing information, infusion reactions can occur during or after Keytruda administration, and symptoms may include chills, fatigue, headache, nausea, vomiting, and fever [1]. It is crucial that healthcare providers closely monitor patients for these symptoms and take appropriate measures to manage any infusion reactions that occur.

In summary, while there is no explicit information indicating that immunocompromised individuals are more prone to infusion reactions from Keytruda, healthcare providers should exercise caution and closely monitor patients for any symptoms during and after infusion.

Sources:
[1] Keytruda (pembrolizumab) Prescribing Information. Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. January 2023. <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>